– USA, MA – Rapid Micro Biosystems, a leading provider of automated, non-destructive, rapid microbial detection, announced today that its Board of Directors has named seasoned industry veteran Robert Spignesi as the company’s next chief executive officer. As the new CEO of Rapid Micro Biosystems, Rob’s priorities will be leading the Company to support the business expansion and widespread adoption of the Growth Direct™ System.
Rob has more than 20 years of leadership experience and joined Rapid Micro Biosystems most recently from Thermo Fisher Scientific, where he was a Vice President and General Manager, Americas. Previously, Rob was the VP of Global Strategy, Marketing and Business Development for Fisher Scientific and held senior roles at McKesson Corporation and its affiliates, including EVP Operations and Development and Vice President of Sales and Business Development within the pharmacy systems and automation group. Earlier in his career, he was a senior consultant within the Life Sciences and Healthcare practice of Deloitte Consulting and an aviation officer with the U.S. Army. Rob holds a B.S. in economics from the United States Military Academy at West Point and an MBA from Columbia University where he was the Dr. Donald Bibeault Scholar.
“Rob is the perfect fit for Rapid Micro Biosystems,” said Richard Kollender, Chairman of the Board of Rapid Micro Biosystems and Partner at Quaker Partners. “His industry experience and proven track record of leading business growth provides the right blend of skills to lead the business forward.”
“I am excited to join Rapid Micro Biosystems at such a pivotal time in the company’s history,” commented Mr. Spignesi. “With the launch of the Growth Direct™ and the positive customer response, I am eager to lead the organization through this exciting phase of growth.”
About Rapid Micro Biosystems:
Rapid Micro Biosystems delivers the Growth Direct™ System, an automated, non-destructive rapid detection and enumeration technology based on the compendial method for microbial quality control in pharmaceutical manufacturing. The system automates and accelerates detection and enumeration in the areas of sterility testing, environmental monitoring, and bioburden testing, eliminating manual steps and analysis. The detection technology, first developed and patented by Dr. Don Straus, Ph.D., uses the natural auto-fluorescence of microbes and requires no reagents.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
